Revenue
2022
2023
2024
2025
Aldeyra Therapeutics, Inc. (ALDX)
Price$1.50Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2021
2022
2023
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Research & development | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M | $24.7M | $44.4M | $29.8M | $16.3M | $13.2M | $7.6M | $3.7M | $1.5M |
| Operating expenses | $35.3M | $60.1M | $42.8M | $62.7M | — | — | — | — | — | — | — | — | — |
| Operating income | −$35.3M | −$60.1M | −$42.8M | −$62.7M | −$56.2M | −$36.4M | −$63.1M | −$39.7M | −$22.5M | −$18.7M | −$12.0M | −$7.3M | −$3.7M |
| EBITDA | −$35.0M | −$59.9M | −$42.5M | −$62.4M | −$56.0M | −$36.4M | −$63.0M | −$39.6M | −$22.5M | −$18.7M | −$12.0M | −$7.3M | — |
| Net income | −$33.8M | −$55.9M | −$37.5M | −$62.0M | −$57.8M | −$37.6M | −$60.8M | −$38.9M | −$22.3M | −$18.7M | −$12.1M | −$5.2M | $13.1M |
| Basic EPSper basic share | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | -$1.11 | -$2.24 | -$1.79 | -$1.40 | -$1.65 | -$1.40 | -$2.51 | $3.49 |
| Diluted EPSper diluted share | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | -$1.11 | -$2.24 | -$1.79 | -$1.40 | -$1.65 | -$1.40 | -$3.09 | -$17.61 |
Owners
Reported shareholders
≈9.74%of listed shares
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / EDELMAN JOSEPH / PERCEPTIVE ADVISORS LLC5.88M shares · Apr 3, 2025
View holders
| Holder | % owned |
|---|---|
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / EDELMAN JOSEPH / PERCEPTIVE ADVISORS LLC | ≈9.74%5.88M shares |
Knoll Capital Management, LLC | 9.08%5.48M shares |
AQR CAPITAL MANAGEMENT LLC | 6.22%3.75M shares |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 4.40%2.65M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.92%2.36M shares |
D. E. Shaw & Co., Inc. | 3.22%1.94M shares |
Brady Todd C | ≈2.85%1.72M shares |
MARSHALL WACE, LLP | 2.50%1.51M shares |
683 Capital Management, LLC | 2.40%1.45M shares |
JANE STREET GROUP, LLC | 2.28%1.38M shares |
BlackRock, Inc. | 2.08%1.26M shares |
Qube Research & Technologies Ltd | 1.87%1.13M shares |
ACADIAN ASSET MANAGEMENT LLC | 1.76%1.06M shares |
ARDSLEY ADVISORY PARTNERS LP | 1.62%975K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.46%882K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.32%794.86K shares |
GOLDMAN SACHS GROUP INC | 1.20%725.44K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.07%646.84K shares |
MORGAN STANLEY | 1.01%608.32K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.99%596.03K shares |
Percentages use 60.32M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026Form 4 | Brady Todd CPresident and CEO | BuyCommon Stock | 250.0K | $1.67 | $417.5K | 1.72M |
| Mar 19, 2026Form 4 | DOUGLAS RICHARDDirector | BuyCommon Stock | 70.0K | $1.40 | $98.0K | 195.0K |
| Mar 18, 2026Form 4 | Alfieri MichaelPrincipal Financial Officer | BuyCommon Stock | 5.0K | $1.42 | $7.1K | 7.5K |
| Aug 13, 2025Form 4 | Alfieri MichaelPrincipal Financial Officer | BuyCommon Stock | 2.5K | $5.30 | $13.3K | 2.5K |
| Aug 11, 2025Form 4 | Machatha StephenChief Development Officer | SellCommon Stock | 22.1K | $5.15 | $113.7K | 221.8K |